Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: Int Immunopharmacol. 2011 Jan 18;11(7):859–869. doi: 10.1016/j.intimp.2011.01.004

Table 1.

Tibia tumors produced by PC-3MM2 cells are dependent on production of IL-6 by tumor cells and macrophages

Experiment groups Tumor incidence Tumor size (g)
Median (range)		 Incidence of lymph
node metastasis
PBS
    PC-3MM2 19/20 1.1 (0–1.4) 19/20
    PC-3MM2-NS shRNA 19/20 1.1 (0–1.3) 19/20
    PC-3MM2-IL-6 shRNA 19/20 0.5 (0–1)*   9/20*
PBS Liposome
    PC-3MM2 20/20 1.2 (0.6–1.2) 20/20
    PC-3MM2-NS shRNA 20/20 1.2 (0.6–1.6) 20/20
    PC-3MM2-IL-6 shRNA 19/20 0.4 (0–1.1)*   11/20*
Clodronate Liposome
    PC-3MM2 20/20 0.6 (0.2–1.1)† 13/20†
    PC-3MM2-NS shRNA 20/20 0.6 (0.2–1)† 10/20†
    PC-3MM2-IL-6 shRNA 20/20 0.3 (0.1–0.8)*,†   1/20†
*

Statistically significant as compared with untreated mice bearing PC-3MM2 bone tumors in the same treatment groups (p<0.05).

†

Statistically significant as compared with mice bearing bone tumors produced by PC-3MM2, or PC-3MM2-NS shRNA, or PC-3MM2-IL-6 shRNA in the different treatment groups (p<0.05)